We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01598584
Recruitment Status : Withdrawn (Gemcitabine is not the first choice for most pancreatic cancer patients nowdays)
First Posted : May 15, 2012
Last Update Posted : September 28, 2015
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : December 2015
  Estimated Study Completion Date : December 2015